Progress toward poliomyelitis eradication--Nigeria, January 2004-July 2005.

From: Morbidity and Mortality Weekly Report | Date: September 9, 2005 | Copyright information

After the 1988 World Health Assembly resolution to eradicate polio (1), the number of countries where polio is endemic decreased from 125 in 1988 to six * in 2003. However, the Global Polio Eradication Initiative faced critical challenges during 2003-2005, when a resurgence of polio cases occurred across Africa. Nigeria, the most populous ([dagger]) country of the continent, experienced increased wild poliovirus (WPV) transmission throughout the country after suspension of suppleme...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Hepatitis A vaccination coverage among children aged 24-35 months--United States, 2003.
Morbidity and Mortality Weekly Report ; Hepatitis A vaccine was first licensed in the United States in 1995. In 1996, the Advisory Committee on Immunization Practices (ACIP) recommended vaccination of children aged [greater than or equal to] 24 months in populations with the highest incidence of hepatitis A (e.g., American Indian/Alaska
Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease.(Notice to Readers)
Morbidity and Mortality Weekly Report ; On October 17, 2007, the Food and Drug Administration approved quadrivalent meningococcal conjugate vaccine (MCV4) (Menactra[R], Sanofi Pasteur, Swiftwater, Pennsylvania) for use in children aged 2-10 years, in addition to its prior approval for use in persons aged 11-55 years (1). Previous
Hepatitis A vaccination coverage among children aged 24-35 months--United States, 2004-2005.(Table)
Morbidity and Mortality Weekly Report ; After the licensure of hepatitis A vaccine in 1995 for children aged [greater than or equal to] 24 months, the Advisory Committee on Immunization Practices (ACIP) incrementally expanded the proportion of children for whom it recommended the vaccine. In 1996, ACIP recommended vaccinating children in
Improved supply of meningococcal conjugate vaccine, recommendation to resume vaccination of children aged 11-12 years.(Advisory Committee on Immunization Practices)
Morbidity and Mortality Weekly Report ; In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine (MCV4) (Menactra[TM], Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11-55 years. The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination
Expansion of use of live attenuated influenza vaccine (FluMist[R]) to children aged 2-4 years and other FluMist changes for the 2007-08 influenza season.(Notice to Readers)
Morbidity and Mortality Weekly Report ; On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist[R], a live, attenuated influenza vaccine (LAIV), to children aged 2-4 years (i.e., 24-49 months). FluMist is an intranasally administered
Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated.
Morbidity and Mortality Weekly Report ; This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24-59 months who are either unvaccinated or who have a lapse in PCV7 administration. * In February 2000, PCV7, marketed as Prevnar[R] and manufactured by Wyeth Vaccines
Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
Morbidity and Mortality Weekly Report ; Streptococcus pneumoniae (pneumococcus) is a leading cause of pneumonia and meningitis in the United States and disproportionately affects young children and the elderly. In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in the United States for routine use in children aged
Influenza vaccination coverage among children aged 6-59 months--six immunization information system sentinel sites, United States, 2006-07 influenza season.(Survey)
Morbidity and Mortality Weekly Report ; In June 2006, the Advisory Committee on Immunization Practices (ACIP) expanded its 2004 recommendation for routine influenza vaccination of children aged 6-23 months to include children aged 24-59 months. The 2006 ACIP recommendations also reemphasized that previously unvaccinated children aged
Disabilities among children aged less than or equal to 17 years - United States, 1991-1992.
Morbidity and Mortality Weekly Report ; Disabilities among children result in substantial reductions in quality of life and are associated with increased dependence on the health-care and social-service systems. To assess the prevalence of disabilities and their associated health conditions among children, CDC reviewed data from the
Physical activity levels among children aged 9-13 years--United States, 2002.(Illustration)
Morbidity and Mortality Weekly Report ; Three national health objectives for 2010 (objectives no. 22-6, 22-7, and 22-11) aim to increase levels of physical activity and reduce sedentary behavior among children and adolescents (1). To promote a healthy, more active lifestyle among U.S. youth, CDC developed the Youth Media Campaign (YMC),